These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 35563534)

  • 1. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
    Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
    Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
    Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
    Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.
    Mendez-Sanchez N; Cruz-Ramon VC; Ramirez-Perez OL; Hwang JP; Barranco-Fragoso B; Cordova-Gallardo J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
    Musso G; Saba F; Cassader M; Gambino R
    Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
    Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
    Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron overload in nonalcoholic steatohepatitis.
    Fujita N; Takei Y
    Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
    Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
    Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-metabolic interactions in homeostasis and the progression to NASH.
    Hoogerland JA; Staels B; Dombrowicz D
    Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
    Michelotti A; de Scordilli M; Palmero L; Guardascione M; Masala M; Roncato R; Foltran L; Ongaro E; Puglisi F
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.